An alternative to statins may help reduce deaths from heart disease among people with high levels of LDL, or “bad” cholesterol, new research finds.
When taken as a daily pill, bempedoic acid lowered LDL cholesterol and showed a significant 39% reduction in deaths from heart disease and heart attacks, researchers reported Saturday at the American Diabetes Association annual meeting. The findings were simultaneously published in JAMA.
“What we saw really surprised me,” said the study’s lead author, Dr. Steven Nissen, academic director of the Cleveland Clinic’s Heart, Vascular and Thoracic Institute. “I hope this is a wake-up call for patients and doctors.”
Right now, less than half of the people who should be prescribed a cholesterol-lowering drug because of the risk of heart disease are receiving it, according to Nissen. That has to change, she said.
“Treating people who have risk factors before their first cardiovascular event would have great benefits,” not only in preventing complications but also in preventing deaths, he said.
What is a healthy cholesterol level?
Bempedoic acid, which was approved in 2020 by the Food and Drug Administration, is not as effective as statins, which are considered the gold standard in the treatment of high cholesterol. However, many people stop or refuse to take statins because of possible side effects, such as muscle pain, headaches, sleep problems, and digestive problems.
Recent research found that about 20% of people at high risk for heart disease refuse to take statins when prescribed by their doctor. Women in particular were less likely to accept a statin prescription, according to the study published in JAMA Network Open.
Although the new study looked only at the impact of bempedoic acid in people who had adverse reactions to statins, it found that lowering cholesterol resulted in a significant decrease in heart attacks and heart disease-related deaths.
The most important thing is to bring your blood cholesterol to healthy levels, whether you’re taking a statin or bempedoic acid or another lipid-lowering drug, Nissen said in an interview.
LDL, or low-density lipoprotein, is the type of cholesterol that contributes to the buildup of fatty deposits in the arteries and increases the risk of cardiovascular events, such as heart attacks and strokes. According to the American Heart Associationthe optimal total cholesterol level for an adult is approximately 150 mg/dL, with LDL levels of 100 mg/dL or less.
The 4,206 patients enrolled in the new study are part of a larger group described in a New England Journal of Medicine article published in March. The NEJM study included both patients who had suffered a cardiovascular event, such as a stroke or heart attack, and those who only had risk factors.
In the new research, Nissen and his colleagues focused only on participants who had never been diagnosed with heart disease but were at high risk due to factors such as high LDL, diabetes and high blood pressure.
The average age of the participants in the new study was 68 years, and 59% were women. Two thirds had diabetes. At the start, the average LDL level in the participants was 142.5 mg/dL.
At six months into the study, compared to patients taking a placebo, participants receiving a daily dose of bempedoic acid experienced a 23.2% reduction in LDL cholesterol and a 22.7% decrease in inflammation caused by a protein in the blood associated with heart and stroke risk.
Other key findings from the study, which followed most of the participants for just over three years, showed that:
- The risk of heart attacks among people who received the drug was reduced by 39%.
- The risk of death related to heart disease was reduced by 39%.
- The combined risk of a patient dying, having a heart attack or stroke was reduced by 36%.
There was a small increased risk of complications in those receiving bempedoic acid treatment compared with placebo, including the development of gout and gallstones.
Statins as ‘first-line therapy’
While bempedoic acid may not cause as many muscle-related symptoms, it is more expensive than generic statins, cardiologist Dr. Druv S. Kazi noted in an editorial accompanying the JAMA study.
“Patients are likely to face substantially higher out-of-pocket costs for bempedoic acid than for a generic statin,” Kazi wrote.
Sheldon Koenig, CEO and president of Esperion, which makes the drug sold as Nexletol and funded the study, said the drug is now covered by many insurance companies.
“For Medicare, the company has preferred status and the copay is typically only $45 per month,” Koenig said.
The new findings are “exciting and very promising,” said Dr. Marc Eisenberg, a cardiologist and associate professor of medicine at Columbia University’s Vegelos College of Physicians and Surgeons. “But statins have yet to be offered and tested as first-line therapy.” Eisenberg was not associated with the new study.
While the study is “well designed,” Eisenberg said, “we still need more studies.”
These “are very important findings,” said Dr. Robert Rosenson, director of metabolism and lipids at Mount Sinai Health System and professor of medicine at the Icahn School of Medicine at Mount Sinai.
The benefits seen in the new study are greater than would be expected simply based on the observed reductions in LDL levels, said Rosenson, who was not involved in the research.
The new study reinforces the idea that “targeting LDL cholesterol reduces cardiovascular risk,” said Dr. Jeffrey Berger, director of the Center for Cardiovascular Disease Prevention at NYU Langone Health.
Patients with risk factors, such as high LDL and diabetes, but who have not yet been diagnosed with cardiovascular disease “are the largest group of patients we see,” Berger said. Berger was not part of the new study.
For people who can’t or won’t take statins, bempedoic acid offers an alternative, Berger said.
“But I think it’s important to recognize that there are significant side effects with this drug. Like everything in medicine, there are risks and benefits,” Berger said.

